No Data
No Data
Stocks Most Shunned by Hedge Funds and Mutual Funds
The Best Place in Oklahoma for a Couple to Live on Only Social Security
J&J Says Rybrevant Combo Bests AstraZeneca's Tagrisso in Type of Lung Cancer
Express News | J&J: Overall Safety Profile of Sc Amivantamab Is Consistent With Known Profile of IV Administration
Express News | J&J: Rybrevant(®) Marketing Application Submitted to European Medicines Agency Based on Paloma-3 Study
Express News | J&J: Paloma-3 Study Longer Overall Survival, Progression-Free Survival and Duration of Response Shown With Subcutaneous Amivantamab